Publications by authors named "Deborah L Toppmeyer"

Claim this Profile
P
Preoperative Radiation Boost Results in Low Rates of Re-excision and Reduced Locoregional Treatment Time in Breast Cancer Patients.
Molly A Chakraborty, Zohaib K Sherwani, Lakshmi Rekha Narra, Zeinab Abou Yehia, Nisha Ohri, Deborah L Toppmeyer

Ann Surg Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Remote Tailored Risk Communication and Navigation for Hereditary Genetic Risk Assessment Uptake: Economic Evaluation From the Genetic Risk Assessment for Cancer Education and Empowerment Trial.
Elizabeth A Handorf, Jean A McDougall, Emily Heidt, Jinghua An, Scott T Walters, Deborah L Toppmeyer

JCO Oncol Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study.
Sarah J Fadem, Benjamin F Crabtree, Denalee M O'Malley, Lisa Mikesell, Jeanne M Ferrante, Deborah L Toppmeyer

BMC Prim Care· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of PARP inhibitors in breast cancer.
Karan Pandya, Alyssa Scher, Coral Omene, Shridar Ganesan, Shicha Kumar, Deborah L Toppmeyer

Breast Cancer Res Treat· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
Anita Y Kinney, Scott T Walters, Yong Lin, Shou-En Lu, Arreum Kim, Deborah L Toppmeyer

J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer.
Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Deborah L Toppmeyer

Anticancer Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
Sherene Loi, Roberto Salgado, Peter Schmid, Javier Cortes, David W Cescon, Deborah L Toppmeyer

JCO Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
Mridula A George, Sadaf Qureshi, Coral Omene, Deborah L Toppmeyer, Shridar Ganesan

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center.
Mansi R Shah, Imraan Jan, Jeremy Johns, Kuldip Singh, Pallavi Kumar, Deborah L Toppmeyer

Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Deborah L Toppmeyer

Case Rep Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Kathy S Albain, Robert J Gray, Della F Makower, Amir Faghih, Daniel F Hayes, Deborah L Toppmeyer

J Natl Cancer Inst· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Deborah L Toppmeyer, Michael F Press

Cancer Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Nadine Tung, Banu Arun, Michele R Hacker, Erin Hofstatter, Deborah L Toppmeyer

J Clin Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, Kehua Wu, William T Barry, Deborah L Toppmeyer

J Clin Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathy S Albain, Thomas J Saphner, Deborah L Toppmeyer

JAMA Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, Peter M Ravdin, Della F Makower, Kathleen I Pritchard, Deborah L Toppmeyer

N Engl J Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Deborah L Toppmeyer

N Engl J Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence.
Nancy Chan, Deborah Lynn Toppmeyer

J Clin Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, Kehua Wu, William T Barry, Deborah L Toppmeyer

AAPS J· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Deborah L Toppmeyer

N Engl J Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.
Madhura S Mehta, Sonia C Dolfi, Roman Bronfenbrener, Erhan Bilal, Chunxia Chen, Deborah L Toppmeyer

PLoS One· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes.
Madhura S Mehta, Alexei Vazquez, Diptee A Kulkarni, John E Kerrigan, Gurinder Atwal, Deborah L Toppmeyer

Breast Cancer Res Treat· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone, a new treatment option for metastatic breast cancer.
Deborah L Toppmeyer, Susan Goodin

Am J Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer.
Diptee A Kulkarni, Alexei Vazquez, Bruce G Haffty, Elisa V Bandera, Wenwei Hu, Deborah L Toppmeyer

Carcinogenesis· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
Antoinette R Tan, Deborah L Toppmeyer

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis